Ben Breton
Head of Computational Biology
With over 14 years of pioneering experience in computational biology within the biotech startup sphere, Ben Breton brings a wealth of expertise to Innovac. His profound knowledge spans research and development, regulatory, and clinical applications, making him a key player in the field. Ben's career includes significant roles at notable startups such as Good Start Genetics, Moderna Therapeutics, and Beam Therapeutics.
In 2016, Ben joined the personalized cancer vaccine computational biology team at Moderna. There, he played a crucial role in the rapid development of mRNA-4157, Moderna’s individualized neoantigen therapy, driving it from inception to Phase 1 clinical trials in under two years. Ben accelerated mRNA-4157 program by contributing his expertise to a diverse set of activities, including the neoantigen selection algorithm, IND submissions, NGS sequencing, clinical trial design strategy, and software engineering.
Now at Innovac, as the Head of Computational Biology, Ben applies his sharp focus on innovation and clinical application to develop groundbreaking mRNA vaccines to the clinic.